Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Status:
Recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric patients (age 7 to 11 years)

Phase 3

H. Lundbeck A/S

Takeda

Fluoxetine
Vortioxetine